Abbisko Cayman Limited (HK:2256)
:2256
Top Page
Abbisko Cayman Limited
(2256)
Select Model
Select Model
Rating:57Neutral
Price Target:
HK$13.00
▼(-0.15% Downside)
Action:ReiteratedDate:11/25/25
Abbisko Cayman Limited's overall stock score is primarily influenced by its financial performance, which shows promising revenue growth and improved net income. However, technical indicators suggest bearish momentum, and the stock's high P/E ratio indicates potential overvaluation. The absence of a dividend yield further impacts its valuation negatively.
Positive Factors
Revenue Growth
A 23% top-line increase indicates durable demand or successful advancement of drug candidates; persistent revenue growth over multiple quarters supports scaling R&D, attracts partnership interest, and underpins longer-term cash inflows that can fund development without immediate dilutive financing.
Negative Factors
Negative Operating Cash Flow
Persistent negative operating cash flow is a structural concern for a biotech still investing in development; it forces ongoing dependence on milestone payments, licensing, or capital markets. Until operations generate positive cash, funding risk and execution pressure remain elevated.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
A 23% top-line increase indicates durable demand or successful advancement of drug candidates; persistent revenue growth over multiple quarters supports scaling R&D, attracts partnership interest, and underpins longer-term cash inflows that can fund development without immediate dilutive financing.
Read all positive factors
Abbisko Cayman Limited (2256) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$9.02B
Dividend YieldN/A
Average Volume (3M)4.32M
Price to Earnings (P/E)135.6
Beta (1Y)1.31
Revenue Growth23.37%
EPS GrowthN/A
CountryHK
Employees281
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.49
Shares Outstanding680,105,350
10 Day Avg. Volume4,319,715
30 Day Avg. Volume4,318,146
Financial Highlights & Ratios
PEG Ratio-1.02
Price to Book (P/B)1.56
Price to Sales (P/S)6.07
P/FCF Ratio-150.44
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$22.21Price Target Upside70.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.17
Revenue Forecast (FY)HK$512.62M
Abbisko Cayman Limited Business Overview & Revenue Model
Company Description
Abbisko Cayman Limited, a clinical-stage biopharmaceutical company, discovers and develops small molecule oncology therapies in the People's Republic of China. Its product candidates are primarily small molecules that focus on small molecule preci...
How the Company Makes Money
Abbisko Cayman Limited generates revenue through a multi-faceted approach that includes the development and commercialization of its proprietary drug candidates. The company's primary revenue streams consist of milestone payments from pharmaceutic...
Abbisko Cayman Limited Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
72
Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 618.84M | 503.99M | 19.06M | 0.00 | 22.68M | 0.00 |
| Gross Profit | 618.84M | 503.99M | 19.06M | 0.00 | 22.68M | 0.00 |
| EBITDA | 96.28M | -15.28M | -410.99M | -492.62M | -1.80B | -150.21M |
| Net Income | 149.98M | 28.30M | -431.58M | -498.29M | -1.81B | -706.81M |
Balance Sheet | ||||||
| Total Assets | 2.44B | 2.11B | 2.12B | 2.49B | 2.65B | 665.97M |
| Cash, Cash Equivalents and Short-Term Investments | 2.38B | 2.01B | 1.96B | 2.35B | 2.57B | 636.66M |
| Total Debt | 17.77M | 24.29M | 35.72M | 45.58M | 53.80M | 4.31M |
| Total Liabilities | 217.96M | 148.71M | 134.28M | 143.16M | 118.48M | 1.77B |
| Stockholders Equity | 2.22B | 1.96B | 1.98B | 2.35B | 2.54B | -1.10B |
Cash Flow | ||||||
| Free Cash Flow | 126.03M | -20.32M | -456.98M | -366.64M | -182.08M | -121.60M |
| Operating Cash Flow | 129.00M | -12.92M | -444.73M | -343.90M | -169.74M | -117.56M |
| Investing Cash Flow | 239.41M | -196.50M | 378.52M | -216.57M | -1.46B | -11.25M |
| Financing Cash Flow | 23.09M | -80.86M | -16.11M | -20.81M | 2.10B | 505.89M |
Abbisko Cayman Limited Technical Analysis
Positive
13.02
Price Trends
12.64
Positive
13.32
Negative
13.71
Negative
Market Momentum
0.03
Negative
60.05
Neutral
76.10
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2256, the sentiment is Positive. The current price of 13.02 is above the 20-day moving average (MA) of 12.33, above the 50-day MA of 12.64, and below the 200-day MA of 13.71, indicating a neutral trend. The MACD of 0.03 indicates Negative momentum. The RSI at 60.05 is Neutral, neither overbought nor oversold. The STOCH value of 76.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2256.
Abbisko Cayman Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | HK$9.02B | 135.64 | 7.17% | ― | 23.37% | ― | |
54 Neutral | HK$18.02B | -22.61 | -12.74% | ― | -76.58% | -4.90% | |
53 Neutral | HK$8.81B | -76.25 | -6.26% | ― | 206.58% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$12.80B | 5.89 | 18.28% | ― | 59.70% | 239.97% | |
42 Neutral | HK$13.59B | -15.44 | -64.19% | ― | -55.64% | -158.67% |
* Healthcare Sector Average
HK:2256
Abbisko Cayman Limited
13.26
7.07
114.22%
HK:9966
Alphamab Oncology
9.04
3.11
52.45%
HK:1672
Ascletis Pharma, Inc.
16.98
12.03
243.03%
HK:2142
HBM Holdings Ltd.
14.47
9.04
166.48%
HK:2616
CStone Pharmaceuticals
9.35
7.15
325.00%
HK:6955
Shandong Boan Biotechnology Company., Limited. Class H
6.98
-1.10
-13.61%
Abbisko Cayman Limited Corporate Events
Abbisko’s TGCT Drug Pimicotinib Wins FDA NDA Acceptance After Strong Phase III Data
Jan 13, 2026
Abbisko Cayman Limited announced that its subsidiary Abbisko Therapeutics has had its New Drug Application for pimicotinib, an orally administered and highly selective CSF-1R inhibitor for the systemic treatment of tenosynovial giant cell tumor, f...
Abbisko Wins NMPA IND Clearance for Novel KRAS G12D Cancer Drug ABSK141
Dec 24, 2025
Abbisko Cayman Limited announced that its subsidiary Abbisko Therapeutics has received clearance from China’s National Medical Products Administration for an Investigational New Drug application to begin clinical trials of ABSK141, an oral, ...
Abbisko Wins First Global Approval for TGCT Drug Pimicotinib in China
Dec 22, 2025
Abbisko Cayman Limited announced that its subsidiary Abbisko Therapeutics has received approval from China’s National Medical Products Administration for pimicotinib, a novel, oral, highly selective CSF-1R inhibitor, for adult patients with ...
Abbisko Therapeutics Advances FGFR2/3 Inhibitor for Achondroplasia Treatment
Dec 16, 2025
Abbisko Therapeutics has announced the successful dosing of the first patient in a Phase II clinical study for ABSK061, a selective FGFR2/3 inhibitor, aimed at treating achondroplasia in children. This development marks a significant step in addre...
Abbisko Therapeutics Reports Positive Phase II Results for NSCLC Treatment
Dec 8, 2025
Abbisko Therapeutics has announced promising preliminary results from a Phase II clinical study of its oral PD-L1 inhibitor, ABSK043, in combination with the EGFR inhibitor firmonertinib, for treating non-small cell lung cancer (NSCLC). The study,...
Abbisko Therapeutics Secures FDA Clearance for Pioneering Cancer Drug
Dec 1, 2025
Abbisko Cayman Limited announced that its subsidiary, Abbisko Therapeutics, has received clearance from the U.S. FDA for its Investigational New Drug application for ABSK141, a novel oral small-molecule KRAS G12D inhibitor. This development marks ...
Abbisko Therapeutics Showcases Promising Phase III Results for TGCT Treatment
Nov 17, 2025
Abbisko Therapeutics, a subsidiary of Abbisko Cayman Limited, presented promising long-term efficacy and safety results from its Phase III MANEUVER study of pimicotinib at the CTOS 2025 Annual Meeting. The study demonstrated significant improvemen...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.